Institution
Cancer Epidemiology Unit
About: Cancer Epidemiology Unit is a based out in . It is known for research contribution in the topics: Population & Cancer. The organization has 669 authors who have published 1725 publications receiving 93979 citations.
Topics: Population, Cancer, Breast cancer, European Prospective Investigation into Cancer and Nutrition, Prospective cohort study
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Fatigue prevalence rates differed according to tumour stage, site, age, and sex of the patients, and can be used for the planning of research and clinical routine.
Abstract: Age- and sex-standardised prevalence rates of fatigue in a large hospital-based sample of cancer patients
80 citations
••
TL;DR: Important aspects of use of HRT, such as type of preparation currently being used, are reported very reliably by women completing a self-administered questionnaire.
Abstract: BACKGROUND Epidemiological studies of the effects of hormone replacement therapy (HRT) often rely on exposure data and information on past health from self-administered questionnaires. The accuracy with which women report current use of HRT and the specific preparation in use is not known. This study aims to compare aspects of self-reported use of HRT and treatment for various conditions with data from general practice prescription records. METHODS Reported questionnaire data on use of HRT were compared with those on the general practice prescription record for 570 women participating in the Million Women Study from two general practices in the UK. RESULTS There was excellent agreement between data from the self-administered questionnaire and the prescription record: 96% agreement (kappa = 0.91) for current use of HRT, 95% agreement (kappa = 0.90) for any use of HRT during the period covered by the prescription record, and 97% agreement (kappa = 0.95) among current users for whether the HRT preparation contained oestrogen alone, combined oestrogen/progestogen, or some other constituents. Among former HRT users who provided questionnaire information on the preparation they used most recently, there was 69% agreement on the proprietary preparation used and 97% agreement (kappa = 0.93) on the hormonal constituents used. Agreement between reported treatment for various conditions and the presence of a prescription appropriate for that condition ranged from 89-99% (kappa 0.53-0.92), and was highest for thyroid disease and asthma. CONCLUSION Important aspects of use of HRT, such as type of preparation currently being used, are reported very reliably by women completing a self-administered questionnaire.
79 citations
••
Harvard University1, Brigham and Women's Hospital2, German Cancer Research Center3, Johns Hopkins University4, Imperial College London5, University Medical Center Utrecht6, University of Colorado Denver7, American Cancer Society8, University of Melbourne9, Cancer Council Victoria10, University of Southern California11, Umeå University12, International Agency for Research on Cancer13, University of Hawaii14, University of Murcia15, Aarhus University16, Cancer Epidemiology Unit17, Academy of Athens18
TL;DR: Eight established PCa risk variants were associated with progression to PCSM after diagnosis, and one predicted an increased risk of PCSM, while seven wereassociated with decreased risk.
79 citations
••
International Agency for Research on Cancer1, Harvard University2, Brigham and Women's Hospital3, University of Bristol4, University Hospitals Bristol NHS Foundation Trust5, University of Ioannina6, Imperial College London7, Fred Hutchinson Cancer Research Center8, National Institutes of Health9, Cancer Epidemiology Unit10, University of Leeds11, German Cancer Research Center12, Royal Melbourne Hospital13, University of Melbourne14, Utrecht University15, Kaiser Permanente16, American Cancer Society17, University of Virginia18, University of Barcelona19, Ohio State University20, Cancer Council Victoria21, Cedars-Sinai Medical Center22, Lunenfeld-Tanenbaum Research Institute23, Monash University, Clayton campus24, University of Southern California25, Dresden University of Technology26, University of Washington27, University of North Carolina at Chapel Hill28, Chonnam National University29, University of Hawaii30, Karolinska Institutet31, Karolinska University Hospital32, University of León33, Cornell University34, Memorial Sloan Kettering Cancer Center35, Huntsman Cancer Institute36, Université Paris-Saclay37, Paris Descartes University38, Institut Gustave Roussy39, Johns Hopkins University40, Massey University41, Rappaport Faculty of Medicine42, University of Pittsburgh43, University of Utah44, Wageningen University and Research Centre45, Umeå University46, First Faculty of Medicine, Charles University in Prague47, Charles University in Prague48, Academy of Sciences of the Czech Republic49, Memorial University of Newfoundland50, Vanderbilt University51
TL;DR: In an analysis of blood samples from almost 400,000 participants in the UK Biobank, a higher level of IGF1, determined by genetic factors, was associated with colorectal cancer.
79 citations
••
TL;DR: Neither higher nor lower dose vitamin D supplementation prevented hip fracture, and Randomised and observational data on vitamin D and hip fracture appear to differ.
Abstract: Vitamin D supplementation for fracture prevention is widespread despite conflicting interpretation of relevant randomised controlled trial (RCT) evidence. This study summarises quantitatively the current evidence from RCTs and observational studies regarding vitamin D, parathyroid hormone (PTH) and hip fracture risk. We undertook separate meta-analyses of RCTs examining vitamin D supplementation and hip fracture, and observational studies of serum vitamin D status (25-hydroxyvitamin D (25(OH)D) level), PTH and hip fracture. Results from RCTs were combined using the reported hazard ratios/relative risks (RR). Results from case-control studies were combined using the ratio of 25(OH)D and PTH measurements of hip fracture cases compared with controls. Original published studies of vitamin D, PTH and hip fracture were identified through PubMed and Web of Science databases, searches of reference lists and forward citations of key papers. The seven eligible RCTs identified showed no significant difference in hip fracture risk in those randomised to cholecalciferol or ergocalciferol supplementation versus placebo/control (RR = 1.13[95%CI 0.98-1.29]; 801 cases), with no significant difference between trials of <800 IU/day and ≥800 IU/day. The 17 identified case-control studies found 33% lower serum 25(OH)D levels in cases compared to controls, based on 1903 cases. This difference was significantly greater in studies with population-based compared to hospital-based controls (χ2
1 (heterogeneity) = 51.02, p < 0.001) and significant heterogeneity was present overall (χ2
16 (heterogeneity) = 137.9, p < 0.001). Serum PTH levels in hip fracture cases did not differ significantly from controls, based on ten case-control studies with 905 cases (χ2
9 (heterogeneity) = 149.68, p < 0.001). Neither higher nor lower dose vitamin D supplementation prevented hip fracture. Randomised and observational data on vitamin D and hip fracture appear to differ. The reason for this is unclear; one possible explanation is uncontrolled confounding in observational studies. Post-fracture PTH levels are unrelated to hip fracture risk.
79 citations
Authors
Showing all 669 results
Name | H-index | Papers | Citations |
---|---|---|---|
Richard Peto | 183 | 683 | 231434 |
Kay-Tee Khaw | 174 | 1389 | 138782 |
Silvia Franceschi | 155 | 1340 | 112504 |
Timothy J. Key | 146 | 808 | 90810 |
Hans-Olov Adami | 145 | 908 | 83473 |
Alicja Wolk | 135 | 778 | 66239 |
Paolo Vineis | 134 | 1088 | 86608 |
Lars Klareskog | 131 | 697 | 63281 |
Eva Negri | 129 | 1010 | 66735 |
John A. Baron | 128 | 609 | 61182 |
Jack Cuzick | 128 | 754 | 79979 |
Anders Ekbom | 116 | 613 | 51430 |
C. La Vecchia | 115 | 817 | 53460 |
Valerie Beral | 114 | 471 | 53729 |
Carlo La Vecchia | 112 | 1265 | 56282 |